The global cancer immunotherapy market is growing due to an increasing incidence of cancer and new opportunities are emerging with a concept of deploying immune system to fight the disease. In 2016, the value of the market was at approximately USD 61 bn and the projected CAGR is 14% by 2021. One of the potential therapies is to use superantigens (SAg), which are proteins produced by bacteria or viruses and are one of the most potent activators of the immune system.